Leila Alland
Leila Alland's purchase track record
Leila Alland has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/16/2024 | ABEO | $52K | +8.7% | +29.3% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
PMV Pharmaceuticals Adds Matt Eckler to Board. PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its Board of Directors. This corporate update adds to the company's leadership team. The stock is currently trading near the top of its 52-week range, with an RSI of 69.0 indicating strong recent momentum.
Transaction History
| ABEO | ▼ Sell | Open Market | 11,000 | $65K | 6/30/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 18,065 | $92K | 2/2/2026 | View on chart |
| ABEO | ▲ Buy | Grant | 37,313 | $0 | 1/26/2026 | View on chart |
| ABEO | ▲ Buy | Grant | 36,101 | $0 | 1/31/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 11,797 | $0 | 8/26/2024 | View on chart |
| ABEO | ▲ Buy | Grant | 23,611 | $0 | 7/8/2024 | View on chart |
| ABEO | ▲ Buy | Open Market | 11,000 | $52K | 5/16/2024 | View on chart |
| ABEO | ▼ Sell | Open Market | 7,246 | $28K | 9/27/2023 | View on chart |
| PMVP | ▼ Sell | Open Market | 6,291 | $42K | 9/15/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 58,689 | $271K | 6/14/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 13,400 | $0 | 9/26/2022 | View on chart |
| PMVP | ▲ Buy | Grant | 52,200 | $0 | 9/9/2022 | View on chart |
| PMVP | ▲ Buy | Option Exercise | 100 | $390 | 9/9/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 100 | $3K | 9/9/2021 | View on chart |
| PMVP | ▲ Buy | Option Exercise | 3,900 | $15K | 9/7/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 3,900 | $118K | 9/7/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth
Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.